A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer

This Phase 3 clinical trial is an essential step in the evaluation of an investigational
medication to see if it may be useful in treating prostate cancer. The purpose of the SPARTAN
study is to compare the safety and effectiveness of the investigational medication to placebo
in delaying prostate cancer from spreading to other parts of the body. A placebo is a pill
that looks like the investigational medication but does not contain any active medication, a
dummy pill.

Phase 3 studies are performed after preliminary evidence suggesting effectiveness of the drug
has been obtained in previous Phase 2 studies. These studies are intended to gather the
additional information about effectiveness and safety that is needed to evaluate the overall
benefit-risk relationship of the drug.

Study participants will take the oral investigational medication daily. One cycle of study
treatment lasts 4 weeks or 28 days. The number of cycles will depend on how you and your
cancer respond to the study medication.

In order for the researchers to evaluate and compare the study results, there are two
different study groups. Study participants will be randomly (like flipping a coin) assigned
to one of these groups:

- One group will receive their current treatment along with the investigational medication

- One group will receive their current medications along with a placebo

The investigational medication will be given to 2 out of every 3 study participants. Neither
you nor the study staff will know which group you are in. However, in case of a medical
emergency, your study doctor can quickly find out which treatment group you are in.

All participants will continue to receive their current treatment along with either the
investigational medication or a placebo. The selections will be random, and you may remain on
investigational treatment until your disease worsens, or until significant side effects occur
or you can no longer tolerate treatment.

Inclusion Criteria:

- Histologically or cytologically confirmed adenocarcinoma of the prostate without
neuroendocrine differentiation or small cell features with high risk for development
of metastases, defined as prostate-specific antigen doubling time (PSADT) less than or
equal to (<=) 10 months. PSADT is calculated using at least 3 prostate-specific
antigen (PSA) values obtained during continuous ADT (androgen deprivation therapy)

- Castration-resistant prostate cancer demonstrated during continuous ADT, defined as 3
PSA rises, at least 1 week apart, with the last PSA greater than (>) 2 nanogram per
milliliter (ng/mL)

- Maintain castrate levels of testosterone within 4 weeks prior to randomization and
throughout the study

- Patients currently receiving bone loss prevention treatment with bone-sparing agents
must be on stable doses for at least 4 weeks prior to randomization

- Patients who received a first generation anti-androgen (for example, bicalutamide,
flutamide, nilutamide) must have at least a 4-week washout prior to randomization AND
must show continuing disease (PSA) progression (an increase in PSA) after washout

- At least 4 weeks must have elapsed from the use of 5-alpha reductase inhibitors,
estrogens, and any other anti-cancer therapy prior to randomization

- At least 4 weeks must have elapsed from major surgery or radiation therapy prior to
randomization

- Eastern Cooperative Oncology Group Performance Status 0 or 1

- Resolution of all acute toxic effects of prior therapy or surgical procedure to Grade
<= 1 or baseline prior to randomization

- Adequate organ function according to protocol-defined criteria

- Administration of growth factors or blood transfusions will not be allowed within 4
weeks of the hematology labs required to confirm eligibility

Exclusion Criteria:

- Presence of confirmed distant metastases, including central nervous system and
vertebral or meningeal involvement

- Symptomatic local or regional disease requiring medical intervention

- Prior treatment with second generation anti-androgens

- Prior treatment with CYP17 inhibitors

- Prior treatment with radiopharmaceutical agents, or any other investigational agent
for non-metastatic castration-resistant prostate cancer

- Prior chemotherapy for prostate cancer except if administered in the
adjuvant/neoadjuvant setting

- History of seizure or condition that may pre-dispose to seizure

- Concurrent therapy with protocol-defined excluded medications

- History or evidence of any of the following conditions: any prior malignancy (other
than adequately treated basal cell or squamous cell skin cancer, superficial bladder
cancer, or any other cancer in situ currently in complete remission) within 5 years
prior to randomization; severe/unstable angina, myocardial infarction, symptomatic
congestive heart failure, arterial or venous thromboembolic events, or clinically
significant ventricular arrhythmias within 6 months prior to randomization;
uncontrolled hypertension; gastrointestinal disorder affecting absorption; active
infection; and, any other condition that, in the opinion of the investigator, would
impair the patient's ability to comply with study procedures